Paswan M, Tudu H, Gupta S, Banerjee S, Tirkey D
J Family Med Prim Care. 2025; 13(12):5861-5867.
PMID: 39790752
PMC: 11709009.
DOI: 10.4103/jfmpc.jfmpc_1086_24.
Koyanagi T, Saga Y, Takahashi Y, Tamura K, Takahashi S, Taneichi A
Cancer Rep (Hoboken). 2024; 7(12):e70100.
PMID: 39710372
PMC: 11663491.
DOI: 10.1002/cnr2.70100.
Yang L, Yang M, Chen L, Shen Y, He Y, Meng Z
Front Oncol. 2024; 14:1457294.
PMID: 39582538
PMC: 11581972.
DOI: 10.3389/fonc.2024.1457294.
Li R, Liu H, Liu Y
Front Immunol. 2024; 15:1447719.
PMID: 39445027
PMC: 11496054.
DOI: 10.3389/fimmu.2024.1447719.
Zhang Z, Liu X, Chu C, Zhang Y, Li W, Yu X
Cell Death Dis. 2024; 15(10):735.
PMID: 39384743
PMC: 11464496.
DOI: 10.1038/s41419-024-07120-8.
Evaluating Ovarian Cancer Chemotherapy Response Using Gene Expression Data and Machine Learning.
Amniouel S, Yalamanchili K, Sankararaman S, Jafri M
BioMedInformatics. 2024; 4(2):1396-1424.
PMID: 39149564
PMC: 11326537.
DOI: 10.3390/biomedinformatics4020077.
Organ-on-a-chip: future of female reproductive pathophysiological models.
Deng Z, Dai F, Wang R, Deng H, Yin T, Cheng Y
J Nanobiotechnology. 2024; 22(1):455.
PMID: 39085921
PMC: 11290169.
DOI: 10.1186/s12951-024-02651-w.
Histopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction.
Kilim O, Olar A, Biricz A, Madaras L, Pollner P, Szallasi Z
medRxiv. 2024; .
PMID: 38883738
PMC: 11177907.
DOI: 10.1101/2024.06.01.24308293.
miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.
Delek F, Tuncer S, Odemis D, Erciyas S, Sukruoglu Erdogan O, Saip P
Biochem Genet. 2024; .
PMID: 38705961
DOI: 10.1007/s10528-024-10819-0.
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.
Bhadra M, Sachan M, Nara S
Front Mol Biosci. 2024; 11:1361601.
PMID: 38690293
PMC: 11058280.
DOI: 10.3389/fmolb.2024.1361601.
Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma.
Zelisse H, Hwan R, van de Vijver M, Dijk F, Mom C, Hooijer G
Virchows Arch. 2024; 486(2):381-391.
PMID: 38622323
PMC: 11876211.
DOI: 10.1007/s00428-024-03807-7.
Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.
Pampeno C, Opp S, Hurtado A, Meruelo D
Int J Mol Sci. 2024; 25(5).
PMID: 38474178
PMC: 10932354.
DOI: 10.3390/ijms25052925.
Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E, Clemente V, Grube M, Svedbom A, Nelson A, Blome F
JAMA Netw Open. 2024; 7(2):e240407.
PMID: 38411963
PMC: 10900967.
DOI: 10.1001/jamanetworkopen.2024.0407.
Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes.
Takahashi C, Chtcherbinine M, Huddle B, Wilson M, Emmel T, Hohlman R
Chem Biol Interact. 2024; 391:110910.
PMID: 38364885
PMC: 11062403.
DOI: 10.1016/j.cbi.2024.110910.
A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients.
Xiong T, Wang Y, Zhu C
Diagn Pathol. 2024; 19(1):4.
PMID: 38178187
PMC: 10765690.
DOI: 10.1186/s13000-023-01414-9.
Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.
Ryu J, Boylan K, Twigg C, Evans R, Skubitz A, Thomas S
Clin Proteomics. 2024; 21(1):1.
PMID: 38172678
PMC: 10762856.
DOI: 10.1186/s12014-023-09447-4.
Exposure to select PFAS and PFAS mixtures alters response to platinum-based chemotherapy in endometrial cancer cell lines.
Rickard B, Overchuk M, Tulino J, Tan X, Ligler F, Bae-Jump V
Environ Health. 2023; 22(1):87.
PMID: 38098045
PMC: 10720226.
DOI: 10.1186/s12940-023-01034-2.
The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.
Koyanagi T, Saga Y, Takahashi Y, Tamura K, Yoshiba T, Takahashi S
Cancer Rep (Hoboken). 2023; 7(1):e1934.
PMID: 38013666
PMC: 10809274.
DOI: 10.1002/cnr2.1934.
RIPK1 polymorphisms and expression levels: impact on genetic susceptibility and clinical outcome of epithelial ovarian cancer.
Wang X, Deng K, Tao J, Zou J, Du Y, Dai L
Cancer Cell Int. 2023; 23(1):290.
PMID: 37996860
PMC: 10668399.
DOI: 10.1186/s12935-023-03139-7.
Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D, Zhu H, Wang T, Zhang Y, Zheng X, Qu Y
Eur J Med Res. 2023; 28(1):465.
PMID: 37884970
PMC: 10604403.
DOI: 10.1186/s40001-023-01376-0.
